Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from China Isotope & Radiation Corp. ( (HK:1763) ).
China Isotope & Radiation Corporation has called its first extraordinary general meeting of 2026 for 9 January in Beijing, where shareholders will vote on renewing a series of key framework agreements covering products and services supply, products and services purchase, engineering construction services and financial services, each with proposed new annual caps. The meeting arrangements detail eligibility, share registration closure, and proxy procedures, underscoring the importance of these related operational and financial agreements for the company’s ongoing business activities and governance, and giving shareholders a formal opportunity to approve or reject the terms that will shape its commercial and funding relationships in the coming years.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a PRC-incorporated joint stock company listed in Hong Kong, operating in the nuclear medicine and radiation-related sector, with a board comprising executive, non-executive and independent non-executive directors overseeing its governance and strategic direction.
Average Trading Volume: 369,156
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.46B
For detailed information about 1763 stock, go to TipRanks’ Stock Analysis page.